Crucell N.V.
Archimedesweg 4
P.O. Box 2048
CA Leiden
2301
Tel: 31-0-71-524-8701
Fax: 31-0-71-524-8702
Website: http://www.crucell.com/
Email: info@crucell.com
269 articles about Crucell N.V.
-
Ebola Clinical Trials: Big Name Players In The Ebola Race
10/28/2014
-
Johnson & Johnson Jumps Into The Ebola Race With Collaboration Of Crucell And Bavarian Nordic; Human Trials To Start In Early 2015
9/4/2014
-
Mucosis B.V. Signs Research and License Option Agreement With Crucell N.V.
10/8/2012
-
CLC bio Delivers Specialized Antibody Engineering and Selection Software for Crucell N.V.
6/8/2012
-
ARTES Biotechnology Announces a Strategic Collaboration Deal for Vaccine Development
4/24/2012
-
Judgment Issued in Crucell N.V. Buy-Out Proceedings
2/28/2012
-
Crucell N.V. Release: Promising Results of Novel Combination Vaccine
1/5/2012
-
Crucell N.V. Discovers Important New Antibody Against Influenza A
7/8/2011
-
Isconova Enters into Adjuvant License Agreement with Crucell N.V.
6/9/2011
-
Crucell N.V., GlaxoSmithKline And PATH MVI Partner to Develop Second-Generation Vaccine Against Malaria
6/7/2011
-
Crucell N.V. Intends to Delist Ordinary Shares on NYSE Euronext
3/15/2011
-
Johnson & Johnson Acquires 98.89% of Crucell N.V. Shares
3/9/2011
-
Johnson & Johnson Completes Tender Offer for Crucell N.V. and Declares Offer Unconditional
2/22/2011
-
Johnson & Johnson Completes Tender Offer for Crucell N.V. and Declares Offer Unconditional
2/22/2011
-
Crucell N.V. Release: Minimum Acceptance Condition Satisfied
2/18/2011
-
Crucell N.V. Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
2/8/2011
-
Crucell N.V. Swings to Full-Year Net Loss
2/7/2011
-
Crucell N.V. Reports Fourth Quarter and Full Year 2010 Results
2/7/2011
-
Johnson & Johnson Receives Approval from European Commission
1/31/2011
-
Johnson & Johnson Launches $2.3 Billion Bid for Crucell N.V.
12/8/2010